Repare Therapeutics Inc.2024财年第二财季实现净利润-34.77百万美元，同比减少190.96%

自选股智能写手08-17 00:00

8月17日，Repare Therapeutics Inc.（RPTX.US）公布财报，公告显示公司2024财年第二财季净利润为-34.77百万美元，同比减少190.96%；其中营业收入为1.07百万美元，同比减少96.46%，每股基本收益为-0.82美元。从资产负债表来看，Repare Therapeutics Inc.（RPTX.US）总负债31.67百万美元，其中短期债务1.96百万美元，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460124994?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-17 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460124994","market":"us","top_or_hot":-1,"title":"Repare Therapeutics Inc.2024财年第二财季实现净利润-34.77百万美元，同比减少190.96%","media":"自选股智能写手","content":"<div>\n<p>8月17日，Repare Therapeutics Inc.（RPTX.US）公布财报，公告显示公司2024财年第二财季净利润为-34.77百万美元，同比减少190.96%；其中营业收入为1.07百万美元，同比减少96.46%，每股基本收益为-0.82美元。从资产负债表来看，Repare Therapeutics Inc.（RPTX.US）总负债31.67百万美元，其中短期债务1.96百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000533959f2caf&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Repare Therapeutics Inc.2024财年第二财季实现净利润-34.77百万美元，同比减少190.96%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRepare Therapeutics Inc.2024财年第二财季实现净利润-34.77百万美元，同比减少190.96%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-17 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000533959f2caf&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月17日，Repare Therapeutics Inc.（RPTX.US）公布财报，公告显示公司2024财年第二财季净利润为-34.77百万美元，同比减少190.96%；其中营业收入为1.07百万美元，同比减少96.46%，每股基本收益为-0.82美元。从资产负债表来看，Repare Therapeutics Inc.（RPTX.US）总负债31.67百万美元，其中短期债务1.96百万美元，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000533959f2caf&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RPTX","symbol_name":"Repare Therapeutics Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000533959f2caf&s=b","article_id":"2460124994","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000533959f2caf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460124994","pubTimestamp":1723824034,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月17日，Repare Therapeutics Inc.公布财报，公告显示公司2024财年第二财季净利润为-34.77百万美元，同比减少190.96%；其中营业收入为1.07百万美元，同比减少96.46%，每股基本收益为-0.82美元。从资产负债表来看，Repare Therapeutics Inc.总负债31.67百万美元，其中短期债务1.96百万美元，资产负债比为0.08，流动比率为0.08。机构评级：截至2024年8月17日，当前有6家机构对Repare Therapeutics Inc.目标价做出预测，其中目标均价为14.67美元，其中最低目标价为8.00美元，最高目标价为25.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"RPTX":"Repare Therapeutics Inc.","LENZ":"Therapeutics"},"translate_title":"Repare Therapeutics Inc. achieved net profits of-US $34.77 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 190.96%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"RPTX":1},"content_text":"8月17日，Repare Therapeutics Inc.（RPTX.US）公布财报，公告显示公司2024财年第二财季净利润为-34.77百万美元，同比减少190.96%；其中营业收入为1.07百万美元，同比减少96.46%，每股基本收益为-0.82美元。从资产负债表来看，Repare Therapeutics Inc.（RPTX.US）总负债31.67百万美元，其中短期债务1.96百万美元，资产负债比为0.08，流动比率为0.08。机构评级：截至2024年8月17日，当前有6家机构对Repare Therapeutics Inc.目标价做出预测，其中目标均价为14.67美元，其中最低目标价为8.00美元，最高目标价为25.00美元。公司简介：Repare Therapeutics Inc 是一家专注于开发基于合成致死性的治疗方法，用于治疗癌症患者的精准医学肿瘤公司。该公司的重点是研究、开发和商业化针对特定基因定义患者群体肿瘤特定易感性的精准肿瘤药物。该公司主要收入来自加拿大。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460124994"}